MannKind (MNKD) Q3 2026 earnings review
MannKind's new heart drug stops growing, but royalties set records
MannKind's newly bought medicine for fluid overload stood still in the quarter it launched a new injector. Revenue grew 24%, because royalties on an inhaled lung drug it makes for United Therapeutics reached their highest level yet. Take out Furoscix, acquired a year ago, and the rest of the business sold about 3% less than last year, by our math. Chief executive Michael Castagna expects a record fourth quarter, yet selling costs turned this one into a $23.2 million loss.
| Sales from businesses it owned a year ago | $79.5M -3% from a year ago |
|---|---|
| Total revenue | $101.9M +24% from a year ago |
| Loss per share | $(0.07) profit of $0.03 a year ago |
| Fourth-quarter outlook | Record quarter by our math at least $112 million, about level with last year |
⚖️ Verdict: 🔴 Bearish
The story got worse, because the product MannKind borrowed to buy is not growing. Furoscix earned no more in its launch quarter than in the one before, so the full-year target of $110 million to $120 million now sits beyond reach by our math, and the company expects no payout on the bonus tied to that level of sales. The good news: royalties from United Therapeutics climbed past their earlier peak, and most Furoscix shipments already use the cheaper new injector.
The question now is whether the fast switch to the autoinjector brings MannKind more patients or merely cheaper packaging for the ones it has. Castagna points to new prescribers and new patients, while the flat revenue says the new form mostly replaced the old one. Furoscix revenue in the fourth quarter will tell, because the switch is nearly complete.
🐂 Bull Case
Its Own Products Now Outsell Its Partner Work
For years United Therapeutics supplied most of MannKind's revenue. It sells Tyvaso DPI, an inhaled treatment for high blood pressure in the lungs that MannKind invented, manufactures and licensed to it. This quarter the three medicines MannKind sells itself passed that partner.
Afrezza, its inhaled insulin, Furoscix, its injection for fluid overload, and the V-Go insulin patch earned $45.0 million between them, double the figure of a year ago. That is 44% of revenue. The partner now supplies 56%, against 72% last year.
The shift matters because one customer, on an order it sets each October, used to decide the revenue line. Selling its own medicines puts pricing and promotion in MannKind's hands, and puts the whole sales bill there too.
What to watch: how much of the record fourth quarter Michael Castagna expects comes from products MannKind promotes itself. A large share would show that the move away from a single customer outlasts the acquisition that began it.
Tyvaso Royalties Reached A New High
MannKind collects a 10% royalty on United Therapeutics' sales of Tyvaso DPI, the inhaled lung medicine it makes for that partner, and keeps nine-tenths of the money after selling a slice in 2023. Growth in that royalty had faded to 4% by June. It reached $37.5 million this quarter, the highest yet.
The money comes from demand MannKind does not control. United Therapeutics sold $379 million of Tyvaso DPI and told investors that patient referrals picked up from September. Castagna expects the licence to deliver "more than $1 billion in revenue from 2027 through 2030".
The other half of the same relationship went the other way. Manufacturing and development work for the partner brought in $19.4 million, a quarter less than last year, which MannKind attributes to delivery timing rather than smaller orders.
What to watch: the royalty line in the fourth quarter. A second increase would show that the slowdown troubling this business through June has ended.
Three In Four Shipments Use The Cheaper Injector
ReadyFlow is an autoinjector that delivers Furoscix, a water-pill given under the skin, in seconds, and it replaces the wearable pump MannKind inherited with the drug. Regulators cleared it in July and shipments began in mid-September.
By late October about 75% of weekly Furoscix shipments used the new form. Finance chief Chris Prentiss said it carries "a meaningfully lower cost of goods" than the pump, and MannKind expects "margins to improve as Furoscix ReadyFlow is adopted into the market".
It needs that improvement, because gross margin on its own medicines eased to 75% from 80%. Castagna said more than 1,600 prescribers wrote their first Furoscix prescription, so cheaper units and new doctors arrived in the same weeks.
What to watch: product gross margin in the fourth quarter, when nearly every shipment will be an autoinjector. A move back toward 80% would turn the switch into profit rather than a cheaper version of the same sales.
🐻 Bear Case
Furoscix Sales Stood Still In Its Launch Quarter
Furoscix is the fluid-overload medicine MannKind bought with scPharmaceuticals a year ago; it drains excess water from heart and kidney patients at home rather than in hospital. Chief executive Michael Castagna said its new autoinjector, ReadyFlow, is "off to an exceptionally strong start".
The revenue says something quieter. Furoscix earned $22.4 million, against $22.2 million in the previous three months. Prentiss said the switch to the autoinjector cost roughly $3 million of sales, because prescribers moved to the new form before MannKind could dispense it.
The year's target was the test of the purchase. MannKind took on $250 million of debt for this medicine and paid its sellers a bonus when ReadyFlow won approval in July. Nine-month sales reached $60.1 million. Add the fourth quarter Castagna described and the year lands near $98 million, short of its own floor.
What to watch: Furoscix revenue for the fourth quarter. The figure Castagna named would still leave the year roughly $12 million below the bottom of the range MannKind set in the spring, and it expects no payout on the bonus tied to that level of sales.
Sales Costs Tripled While Revenue Grew A Quarter
MannKind now spends more on selling its medicines than those medicines earn in gross profit. Selling costs, which cover the field sales teams, promotion and launch work, reached $45.4 million. That equals 44.6% of revenue, against 17.9% a year ago.
MannKind attributes the increase to Furoscix promotion, larger field teams and the two launches. Research spending barely moved. Because overheads climbed while revenue rose more slowly, an operating profit of $18.9 million last year became a loss of $2.2 million.
Prentiss said "2026 was an investment year" and expects spending to stay flat next year. The test is whether sales rise into it. Revenue from everything MannKind owned a year ago fell about 3% by our math, so the enlarged sales force has yet to reach the top line.
What to watch: selling, general and administrative costs as a share of revenue in the fourth quarter. Holding near 60% while revenue sets the record Castagna expects would be the first sign that the spending earns its keep.
Interest Costs Have Risen Sixfold Since Last Year
MannKind borrowed $325 million from Blackstone last year to buy Furoscix. That loan now carries an effective rate of 9.18% and runs to August 2030. Add a sale-and-leaseback of the Danbury plant and a royalty stream sold earlier, and net interest cost $10.6 million this quarter, against $7.3 million last year.
- Cash and investments: $96.6 million, from $176.4 million in December
- Operating cash flow, nine months: minus $58.3 million
- Borrowings: $325 million of principal, at an effective 9.18%
The loan obliges MannKind to hold at least $40 million of ready cash at each quarter end, a test it passed in September. It sold new shares in July to fund the $44.8 million bonus the ReadyFlow approval triggered, and the lenders still hold $50 million of committed money it has not drawn.
What to watch: cash and investments at the end of December, and whether Prentiss delivers the profitable quarter he described. Another quarter of cash going out would bring the next call on investors closer, with $200 million of registered share-selling capacity sitting ready.
Risks this quarter didn't answer
Four standing worries got no fresh numbers in the release, the filing or the call. Each has a disclosure that would settle it, and in each case MannKind offered a different measure or nothing at all.
- Afrezza in adults: Castagna said the adult business "has underperformed this year" and that its share of voice fell about 65%; no adult sales figure followed.
- V-Go, the insulin patch: sales fell 14% to $3.3 million, and nobody said what becomes of the product.
- The 2027 order from United Therapeutics: the contract set an October 15 deadline for the notice, and neither the filing nor the call put a volume on it.
- Afrezza's conversion-dose label: expected in early 2026, unmentioned since.
What to watch: the annual report in February, which should carry the 2027 order volume and a full-year Afrezza figure.
👓 Other Themes
Inhaled Nintedanib Data Arrives In 2028
MannKind's wholly owned inhaled nintedanib, a treatment for scarred lungs, passed its first safety study in patients this quarter. The company cut the next trial to about 150 patients across 85 sites, and Castagna expects "the data readout in the first half of 2028". A meeting with regulators may add American sites and pull that date forward.
Medicare Resets And Tariffs Shape Next Year
Two outside forces land in January. Castagna said the yearly reset of Medicare deductibles stops some patients filling Furoscix, because "they almost would rather go in the hospital than pay the out-of-pocket cost", and he hopes regulators narrow that gap. Separately, MannKind warns that US tariff policy may raise what it pays for raw materials.
💲 Other KPIs
Stock has grown again and now stands 37% above December's level. Work in progress alone rose to $29.5 million from $11.1 million as MannKind built autoinjectors. Inventory now exceeds one quarter of its own product sales, so a slow switch would tie up cash the company cannot spare.
Money United Therapeutics paid before MannKind delivered has fallen for three quarters, to $44.2 million from $55.3 million in December. The balance feeds the revenue line as products ship, so each decline removes a small piece of non-cash support from partner revenue.
The share count MannKind divides its result by rose 4.4% over the year, after July's sale of 10.4 million shares and 2.4 million pre-funded warrants. Owners of 321.6 million shares now hold a company whose books show a $37.3 million shortfall of assets against liabilities.
🔮 Guidance
New. Castagna expects Furoscix to earn about as much in the fourth quarter as in the whole first half, which he put in "the $38 million range" against $22.4 million this quarter. By our math that leaves the year near $98 million, below the $110 million to $120 million MannKind set for the medicine. Medicare deductibles then reset in January.
New. Castagna expects "the best quarter in the history of MannKind". The previous high was the $112.0 million of the fourth quarter of 2025, so by our math a record means revenue roughly level with last year, and about 10% above this quarter. Deliveries to United Therapeutics carry much of that step.
New. Prentiss expects MannKind to earn a profit in the fourth quarter after three losing ones. By our math it must produce about $9.5 million of operating profit to cover its interest bill, which on a record quarter means an operating margin near 8.5%. This quarter it ran at minus 2.1%.
New. Prentiss expects the year's manufacturing and development revenue from United Therapeutics to come out "consistent with the 2025 total". With $77.9 million booked in nine months, that leaves about $28.8 million for the fourth quarter by our math, roughly half again this quarter's $19.4 million. MannKind says delivery timing, not order size, moves the line.
New. MannKind has finished formulating ralinepag as a dry powder and expects to earn $15 million of milestone payments next year, from up to $35 million available under the agreement. United Therapeutics runs the clinical work and decides the pace, so the timing is not MannKind's to set. Nothing lands in 2026.
New. Prentiss expects a profit across 2027 as revenue grows against flat spending, and said the first quarter will not show it. The forecast rests on the switch to the cheaper autoinjector and on the two launches already running, rather than on anything new reaching the market.
❓ Key Questions
How many Furoscix doses did patients actually get?
MannKind reported dose growth every quarter until this one, then moved to shipment shares and prescriber counts. Without doses, nobody can separate real demand from the thin inventory the channel held.
Does the $110 million Furoscix target still stand?
MannKind set a range of $110 million to $120 million for Furoscix this year and said nothing about it this quarter. Its own fourth-quarter figure leaves the year near $98 million by our math.
What did United Therapeutics order for 2027?
The supply contract required the partner's notice by October 15, three weeks before the call. That volume and its price tier set most of next year's manufacturing revenue, and MannKind disclosed neither.
What will ending the $35 pediatric offer cost?
Insurers cover a little more than half of Afrezza's pediatric prescriptions, and the $35 cash programme stops in December. Castagna expects coverage to widen, but put no figure on the revenue at risk.
Where is the promised Afrezza dose-switching label?
MannKind expected a decision on new switching-dose wording in early 2026. Three quarterly reports later it has neither announced the change nor dropped it, and the wording would make moving patients off injections easier.